Forty Seven Inc., a young company moving a humanized IgG4 kappa anti-CD47 monoclonal antibody (MAb) through dual phase I studies, completed the first half of a committed $75 million series A financing led by Lightspeed Venture Partners and Sutter Hill Ventures. Clarus Ventures and GV (formerly Google Ventures) also participated in the financing.